Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 860-866

  Bellone, Stefania ^a   Siegel, Eric R ^b   Cocco, Emiliano ^a   Cargnelutti, Marilisa ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^c   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Epithelial cell adhesion molecule; Epithelial ovarian cancer; Immunohistochemistry; Ovarian tumor marker; Quantitative reverse transcription polymerase chain reaction

Indexed keywords

CARBOPLATIN; DOXORUBICIN; DOXYL; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; MESSENGER RNA; PLATINUM COMPLEX; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ARTICLE; BIOPSY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; OVARY CANCER; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DRUG RESISTANCE; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; OVARY; OVARY TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL ADHESION MOLECULES; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 69449087383     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a8331f     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43-66.
2. Eltabbakh GH. Recent advances in the management of women with ovarian cancer. Minerva Ginecol. 2004;56:81-89.
3. Bignotti E, Tassi RA, Calza S, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 2006;103:405-416.
4. Bignotti E, Tassi RA, Calza S, et al. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol. 2007;196:245.e1-245.e11.
5. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14-25.
6. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77:699-712.
7. Spurr NK, Durbin H, Sheer D, et al. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer. 1986;38:631-636.
8. Kim JH, Herlyn D, Wong KK, et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res. 2003;9:4782-4791.
9. Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356:1981-1982.
10. Spizzo G, Went P, Dirnhofer S, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol. 2006;103:483-488.
11. Naundorf S, Preithner S, Mayer P, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002;100:101-110.
12. Kirman I, Whelan RL. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody. Curr Opin Mol Ther. 2007;9:190-196.
13. Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87:8-16.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
15. McLaughlin PM, Harmsen MC, Dokter WH, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res. 2001;61:4105-4111.
16. Trzpis M, McLaughlin PM, de Leij LM, et al. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171:386-395.
17. Winter MJ, Cirulli V, Briaire-de Bruijn IH, et al. Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem. 2007;302:19-26.
18. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13:3899-3905.